Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

August 20, 2025

Study Completion Date

September 10, 2025

Conditions
Glomerulonephritis
Interventions
DRUG

Finerenone

50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.

DRUG

Placebo

50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.

Trial Locations (1)

21526

RECRUITING

Faculty of Medicine, Aexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER